Lupin receives USFDA approval for Testosterone Topical Solution

25 Oct 2017 Evaluate

Lupin has received final approval for its Testosterone Topical Solution, 30 mg per actuation from the United States Food and Drug Administration (USFDA) to market a generic version of Eli Lilly and Company's Axiron Topical Solution, 30 mg per actuation.

Lupin's Testosterone Topical Solution, 30 mg per actuation is therapeutically equivalent to Eli Lilly and Company's Axiron Topical Solution, 30 mg per actuation. It is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.

Testosterone Topical Solution, 30 mg per actuation, had annual sales of approximately $244.2 million in the US. (IMS MAT June 2017).

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2071.35 -26.30 (-1.25%)
08-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1795.30
Dr. Reddys Lab 1267.15
Cipla 1497.45
Zydus Lifesciences 924.35
Lupin 2071.35
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×